<?xml version="1.0" encoding="UTF-8"?>
<p>The prototype drug for virotherapy is an attenuated herpes simplex virus type 1 (HSV-1), which is engineered to express the human granulocyte–macrophage colony-stimulating factor (GM–CSF) [
 <xref rid="B35-biomedicines-08-00060" ref-type="bibr">35</xref>]. The approved drug known as talimogene laherparepvec (TVEC) has the trade name Imlygic
 <sup>®</sup>. TVEC showed two mechanisms of action, one being the oncolytic effect of infecting and killing tumor cells at the local injection site, and the other being the immunotherapeutic effect through induction of local and systemic immune responses [
 <xref rid="B114-biomedicines-08-00060" ref-type="bibr">114</xref>]. 
</p>
